Cardiovascular Disease in the Systemic Vasculitides

Author(s): Stergios Soulaidopoulos*, Anastasia-Vasiliki Madenidou, Dimitrios Daoussis, Konstantinos Melissaropoulos, Sophie Mavrogeni, George Kitas, Theodoros Dimitroulas

Journal Name: Current Vascular Pharmacology

Volume 18 , Issue 5 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The vasculitides are a heterogeneous group of disorders, characterized by inflammatory cell infiltration and necrosis of blood vessels that cause vascular obstruction or aneurysm formation, affecting various organs such as lungs, kidneys, skin and joints. Cardiac involvement is commonly encountered in primary systemic vasculitis and it is associated with increased morbidity and mortality. Depending on the dominant pathophysiological mechanism, heart complications may manifest in different ways, including myocardial ischemia due to impaired micro- or macrovascular circulation, progressive heart failure following valvular heart disease and myocardial dysfunction, (sub) clinical myocarditis, pericarditis, pulmonary hypertension as well as arteritis of coronary vessels. Beyond cardioprotective regimens, aggressive immunosuppression reduces the inflammatory burden and modulates the progression of cardiovascular complications. Perioperative management of inflammation, when surgical treatment is indicated, improves surgical success rates and postoperative long-term prognosis. We aim to provide an overview of the pathogenetic, diagnostic and therapeutic principles of cardiovascular involvement disease in the various forms of systemic vasculitis.

Keywords: Vasculitis, arteritis, cardiovascular manifestations, takayasu arteritis, kawasaki disease, bechet's disease, ANCA, cardiac magnetic resonance.

[1]
Lane SE, Watts RA, Shepstone L, Scott DGI. Primary systemic vasculitis: clinical features and mortality. QJM 2005; 98(2): 97-111.
[http://dx.doi.org/10.1093/qjmed/hci015 ] [PMID: 15655098]
[2]
Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65(1): 1-11.
[http://dx.doi.org/10.1002/art.37715 ] [PMID: 23045170]
[3]
Mohammad AJ, Jacobsson LTH, Westman KWA, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009; 48(12): 1560-5.
[http://dx.doi.org/10.1093/rheumatology/kep304 ] [PMID: 19797309]
[4]
Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda Vriesman P, Cohen Tervaert JW. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 2013; 28(2): 373-9.
[http://dx.doi.org/10.1093/ndt/gfs428 ] [PMID: 23223225]
[5]
Luqmani R, Suppiah R, Edwards CJ, et al. Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology (Oxford) 2011; 50(4): 697-702.
[http://dx.doi.org/10.1093/rheumatology/keq351 ] [PMID: 21112869]
[6]
Edwards NC, Ferro CJ, Townend JN, Steeds RP. Myocardial disease in systemic vasculitis and autoimmune disease detected by cardiovascular magnetic resonance. Rheumatology (Oxford) 2007; 46(7): 1208-9.
[http://dx.doi.org/10.1093/rheumatology/kem077 ] [PMID: 17478468]
[7]
Keser G, Aksu K. Diagnosis and differential diagnosis of large-vessel vasculitides. Rheumatol Int 2019; 39(2): 169-85.
[http://dx.doi.org/10.1007/s00296-018-4157-3 ] [PMID: 30221327]
[8]
Argyropoulou OD, Protogerou AD, Sfikakis PP. Accelerated atheromatosis and arteriosclerosis in primary systemic vasculitides: current evidence and future perspectives. Curr Opin Rheumatol 2018; 30(1): 36-43.
[http://dx.doi.org/10.1097/BOR.0000000000000453 ] [PMID: 29040156]
[9]
Mavrogeni S, Cantini F, Pohost GM. Systemic vasculitis: an underestimated cause of heart failure - assessment by cardiovascular magnetic resonance. Rev Cardiovasc Med 2013; 14(1): 49-55.
[PMID: 23651986]
[10]
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011; 31(11): 1409-17.
[http://dx.doi.org/10.1007/s00296-011-1999-3 ] [PMID: 21800117]
[11]
Kim ESH, Beckman J. Takayasu arteritis: challenges in diagnosis and management. Heart 2018; 104(7): 558-65.
[http://dx.doi.org/10.1136/heartjnl-2016-310848 ] [PMID: 29175979]
[12]
Seyahi E. Takayasu arteritis: an update. Curr Opin Rheumatol 2017; 29(1): 51-6.
[http://dx.doi.org/10.1097/BOR.0000000000000343 ] [PMID: 27748689]
[13]
Gornik HL, Creager MA. Aortitis. Circulation 2008; 117(23): 3039-51.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.760686 ] [PMID: 18541754]
[14]
Cong X-L, Dai S-M, Feng X, et al. Takayasu’s arteritis: clinical features and outcomes of 125 patients in China. Clin Rheumatol 2010; 29(9): 973-81.
[http://dx.doi.org/10.1007/s10067-010-1496-1 ] [PMID: 20589520]
[15]
Soto ME, Espinola N, Flores-Suarez LF, Reyes PA. Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol 2008; 26(3)(Suppl. 49): S9-S15.
[PMID: 18799047]
[16]
Deyu Z, Guozhang L. Clinical study of aortic regurgitation in patients with aortoarteritis. Int J Cardiol 2000; 75(Suppl. 1): S141-5.
[http://dx.doi.org/10.1016/S0167-5273(00)00189-3 ] [PMID: 10980353]
[17]
Yoshida M, Watanabe R, Ishii T, et al. Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. Int J Rheum Dis 2016; 19(1): 87-94.
[http://dx.doi.org/10.1111/1756-185X.12777 ] [PMID: 26443306]
[18]
Zhang Y, Yang K, Meng X, et al. Cardiac valve involvement in takayasu arteritis is common: a retrospective study of 1,069 patients over 25 years. Am J Med Sci 2018; 356(4): 357-64.
[http://dx.doi.org/10.1016/j.amjms.2018.06.021 ] [PMID: 30360804]
[19]
Slobodin G, Naschitz JE, Zuckerman E, et al. Aortic involvement in rheumatic diseases. Clin Exp Rheumatol 2006; 24(2)(Suppl. 41): S41-7.
[PMID: 16859596]
[20]
Lee GY, Jang SY, Ko SM, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. Int J Cardiol 2012; 159(1): 14-20.
[http://dx.doi.org/10.1016/j.ijcard.2011.01.094 ] [PMID: 21354639]
[21]
Rav-Acha M, Plot L, Peled N, Amital H. Coronary involvement in Takayasu’s arteritis. Autoimmun Rev 2007; 6(8): 566-71.
[http://dx.doi.org/10.1016/j.autrev.2007.04.001 ] [PMID: 17854750]
[22]
Endo M, Tomizawa Y, Nishida H, et al. Angiographic findings and surgical treatments of coronary artery involvement in Takayasu arteritis. J Thorac Cardiovasc Surg 2003; 125(3): 570-7.
[http://dx.doi.org/10.1067/mtc.2003.39 ] [PMID: 12658199]
[23]
Kim H, Barra L. Ischemic complications in Takayasu’s arteritis: A meta-analysis. Semin Arthritis Rheum 2018; 47(6): 900-6.
[http://dx.doi.org/10.1016/j.semarthrit.2017.11.001 ] [PMID: 29198409]
[24]
Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006; 65(9): 1202-7.
[http://dx.doi.org/10.1136/ard.2005.047498 ] [PMID: 16439439]
[25]
Alibaz-Oner F, Yurdakul S, Aytekin S, Direskeneli H. Impaired endothelial function in patients with Takayasu’s arteritis. Acta Cardiol 2014; 69(1): 45-9.
[http://dx.doi.org/10.1080/AC.69.1.3011344 ] [PMID: 24640521]
[26]
Alibaz-Oner F, Koster MJ, Unal AU, et al. Assessment of the frequency of cardiovascular risk factors in patients with Takayasu’s arteritis. Rheumatology (Oxford) 2017; 56(11): 1939-44.
[http://dx.doi.org/10.1093/rheumatology/kex300 ] [PMID: 28968808]
[27]
Sharma BK, Jain S, Radotra BD. An autopsy study of Takayasu arteritis in India. Int J Cardiol 1998; 66(Suppl. 1): S85-90.
[http://dx.doi.org/10.1016/S0167-5273(98)00155-7 ] [PMID: 9951807]
[28]
Ghosh S, Sinha DP, Ghosh S, Mitra D, Kar AK, Panja M. Dilated cardiomyopathy in non-specific aortoarteritis. Indian Heart J 1999; 51(5): 527-31.
[PMID: 10721644]
[29]
Mavrogeni S, Manoussakis MN. Myocarditis and subclavian stenosis in Takayasu arteritis. Int J Cardiol 2011; 148(2): 223-4.
[http://dx.doi.org/10.1016/j.ijcard.2009.05.008 ] [PMID: 19482365]
[30]
Kotake T, Sueyoshi E, Sakamoto I, Izumida S. Myocarditis associated with Takayasu arteritis. Eur Heart J 2015; 36(38): 2564.
[http://dx.doi.org/10.1093/eurheartj/ehv169 ] [PMID: 25994751]
[31]
Melboucy-Belkhir S, Compain C, Sacré K, et al. Recurrent acute pericarditis in Takayasu arteritis. Int J Cardiol 2013; 166(1): 263-5.
[http://dx.doi.org/10.1016/j.ijcard.2012.09.106 ] [PMID: 23040996]
[32]
Fateh-Moghadam S, Huehns S, Schmidt WA, Dietz R, Bocksch W. Pericardial effusion as primary manifestation of Takayasu arteritis. Int J Cardiol 2010; 145(1): e33-5.
[http://dx.doi.org/10.1016/j.ijcard.2008.12.133 ] [PMID: 19193462]
[33]
Hunder GG. Giant cell (temporal) arteritis. Rheum Dis Clin North Am 1990; 16(2): 399-409.
[PMID: 2189157]
[34]
Miloslavsky E, Unizony S. The heart in vasculitis. Rheum Dis Clin North Am 2014; 40(1): 11-26.
[http://dx.doi.org/10.1016/j.rdc.2013.10.006 ] [PMID: 24268007]
[35]
Teixeira A, Capitaine E, Congy F, Herson S, Cherin P. Myopericarditis during Horton disease. Rev Med Interne 2003; 24(3): 189-94.
[http://dx.doi.org/10.1016/S0248-8663(02)00809-3 ] [PMID: 12657441]
[36]
Bablekos GD, Michaelides SA, Karachalios GN, Nicolaou IN, Batistatou AK, Charalabopoulos KA. Pericardial involvement as an atypical manifestation of giant cell arteritis: report of a clinical case and literature review. Am J Med Sci 2006; 332(4): 198-204.
[http://dx.doi.org/10.1097/00000441-200610000-00007 ] [PMID: 17031245]
[37]
Karger B, Fechner G. Sudden death due to giant cell coronary arteritis. Int J Legal Med 2006; 120(6): 377-9.
[http://dx.doi.org/10.1007/s00414-006-0090-1 ] [PMID: 16642350]
[38]
Paulley JW. Coronary ischaemia and occlusion in giant cell (temporal) arteritis. Acta Med Scand 1980; 208(4): 257-63.
[http://dx.doi.org/10.1111/j.0954-6820.1980.tb01190.x ] [PMID: 7446204]
[39]
Tomasson G, Peloquin C, Mohammad A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med 2014; 160(2): 73-80.
[http://dx.doi.org/10.7326/M12-3046 ] [PMID: 24592492]
[40]
Mackie SL, Dasgupta B. Vasculitis syndromes: Dealing with increased vascular risk and mortality in GCA. Nat Rev Rheumatol 2014; 10(5): 264-5.
[http://dx.doi.org/10.1038/nrrheum.2014.38 ] [PMID: 24637366]
[41]
Mohammad AJ, Nilsson J-Å, Jacobsson LTH, Merkel PA, Turesson C. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Ann Rheum Dis 2015; 74(6): 993-7.
[http://dx.doi.org/10.1136/annrheumdis-2013-204652 ] [PMID: 24442881]
[42]
Ninan J, Nguyen A-M, Cole A, et al. Mortality in patients with biopsy-proven giant cell arteritis: a south australian population-based study. J Rheumatol 2011; 38(10): 2215-7.
[http://dx.doi.org/10.3899/jrheum.101254 ] [PMID: 21844141]
[43]
Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis 2015; 74(1): 129-35.
[http://dx.doi.org/10.1136/annrheumdis-2013-204113 ] [PMID: 24095936]
[44]
Säve-Söderbergh J, Malmvall BE, Andersson R, Bengtsson BA. Giant cell arteritis as a cause of death. Report of nine cases. JAMA 1986; 255(4): 493-6.
[http://dx.doi.org/10.1001/jama.1986.03370040067025 ] [PMID: 3941532]
[45]
Bossert M, Prati C, Balblanc J-C, Lohse A, Wendling D. Aortic involvement in giant cell arteritis: current data. Joint Bone Spine 2011; 78(3): 246-51.
[http://dx.doi.org/10.1016/j.jbspin.2010.09.013 ] [PMID: 21030278]
[46]
Marie I, Proux A, Duhaut P, et al. Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine (Baltimore) 2009; 88(3): 182-92.
[http://dx.doi.org/10.1097/MD.0b013e3181a68ae2 ] [PMID: 19440121]
[47]
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation 2017; 135(17): e927-99.
[http://dx.doi.org/10.1161/CIR.0000000000000484 ] [PMID: 28356445]
[48]
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American heart association. Circulation 2004; 110(17): 2747-71.
[http://dx.doi.org/10.1161/01.CIR.0000145143.19711.78 ] [PMID: 15505111]
[49]
Duarte R, Cisneros S, Fernandez G, et al. Kawasaki disease: a review with emphasis on cardiovascular complications. Insights Imaging 2010; 1(4): 223-31.
[http://dx.doi.org/10.1007/s13244-010-0035-6 ] [PMID: 22347918]
[50]
Burns JC. The riddle of Kawasaki disease. N Engl J Med 2007; 356(7): 659-61.
[http://dx.doi.org/10.1056/NEJMp068268 ] [PMID: 17301296]
[51]
Advani N, Sastroasmoro S, Ontoseno T, Uiterwaal CS. Long-term outcome of coronary artery dilatation in Kawasaki disease. Ann Pediatr Cardiol 2018; 11(2): 125-9.
[http://dx.doi.org/10.4103/apc.APC_172_16 ] [PMID: 29922008]
[52]
Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96(6): 1057-61.
[PMID: 7491221]
[53]
Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013; 99(2): 76-82.
[http://dx.doi.org/10.1136/heartjnl-2012-302126 ] [PMID: 22869678]
[54]
Dahdah N. Not just coronary arteritis, Kawasaki disease is a myocarditis, too. J Am Coll Cardiol 2010; 55(14): 1507.
[http://dx.doi.org/10.1016/j.jacc.2009.11.067 ] [PMID: 20359606]
[55]
Takahashi M. Myocarditis in Kawasaki syndrome. A minor villain? Circulation 1989; 79(6): 1398-400.
[http://dx.doi.org/10.1161/01.CIR.79.6.1398 ] [PMID: 2720935]
[56]
de La Harpe M, di Bernardo S, Hofer M, Sekarski N. Thirty years of kawasaki disease: a single-center study at the university hospital of lausanne. Front Pediatr 2019; 7: 11.
[http://dx.doi.org/10.3389/fped.2019.00011 ] [PMID: 30761279]
[57]
Balow JE. Renal vasculitis. Curr Opin Nephrol Hypertens 1993; 2(2): 231-7.
[http://dx.doi.org/10.1097/00041552-199303000-00009 ] [PMID: 7922182]
[58]
Nakamura Y, Ogino H, Matsuda H, Minatoya K, Sasaki H, Kitamura S. Multiple and repetitive anastomotic pseudoaneurysms with polyarteritis nodosa. Ann Thorac Surg 2008; 85(1): 317-9.
[http://dx.doi.org/10.1016/j.athoracsur.2007.07.055 ] [PMID: 18154835]
[59]
Kastner D, Gaffney M, Tak T. Polyarteritis nodosa and myocardial infarction. Can J Cardiol 2000; 16(4): 515-8.
[PMID: 10787467]
[60]
Przybojewski JZ. Polyarteritis nodosa in the adult. Report of a case with repeated myocardial infarction and a review of cardiac involvement. S Afr Med J 1981; 60(13): 512-8.
[PMID: 6116290]
[61]
Mohammad AJ, Bakoush O, Sturfelt G, Segelmark M. The extent and pattern of organ damage in small vessel vasculitis measured by the vasculitis damage index (VDI). Scand J Rheumatol 2009; 38(4): 268-75.
[http://dx.doi.org/10.1080/03009740802668554 ] [PMID: 19296401]
[62]
Holsinger DR, Osmundson PJ, Edwards JE. The heart in periarteritis nodosa. Circulation 1962; 25: 610-8.
[http://dx.doi.org/10.1161/01.CIR.25.4.610 ] [PMID: 13908549]
[63]
Csernok E. New concepts in ANCA detection and disease classification in small vessel vasculitis: the role of ANCA antigen specificity. Mediterr J Rheumatol 2018; 29: 17-20.
[http://dx.doi.org/10.31138/mjr.29.1.17]
[64]
Baena-Díez JM, Garcia-Gil M, Comas-Cufí M, et al. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart 2018; 104(2): 119-26.
[http://dx.doi.org/10.1136/heartjnl-2017-311279 ] [PMID: 28847852]
[65]
Houben E, Penne EL, Voskuyl AE, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology (Oxford) 2018; 57(3): 555-62.
[http://dx.doi.org/10.1093/rheumatology/kex338 ] [PMID: 29029294]
[66]
Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70(3): 488-94.
[http://dx.doi.org/10.1136/ard.2010.137778 ] [PMID: 21109517]
[67]
González-Suárez I, Ríos-Blanco JJ, Arpa J. Accelerated atherosclerosis in ANCA-associated vasculitis. Acta Neurol Scand 2017; 136(6): 688-93.
[http://dx.doi.org/10.1111/ane.12787 ] [PMID: 28608454]
[68]
Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75(9): 1583-94.
[http://dx.doi.org/10.1136/annrheumdis-2016-209133 ] [PMID: 27338776]
[69]
Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90(1): 19-27.
[http://dx.doi.org/10.1097/MD.0b013e318205a4c6 ] [PMID: 21200183]
[70]
McGeoch L, Carette S, Cuthbertson D, et al. Cardiac involvement in granulomatosis with polyangiitis. J Rheumatol 2015; 42(7): 1209-12.
[http://dx.doi.org/10.3899/jrheum.141513 ] [PMID: 25934819]
[71]
Oliveira GHM, Seward JB, Tsang TSM, Specks U. Echocardiographic findings in patients with Wegener granulomatosis. Mayo Clin Proc 2005; 80(11): 1435-40.
[http://dx.doi.org/10.4065/80.11.1435 ] [PMID: 16295023]
[72]
Pugnet G, Gouya H, Puéchal X, et al. Cardiac involvement in granulomatosis with polyangiitis: a magnetic resonance imaging study of 31 consecutive patients. Rheumatology (Oxford) 2017; 56(6): 947-56.
[http://dx.doi.org/10.1093/rheumatology/kew490 ] [PMID: 28339663]
[73]
Goodfield NE, Bhandari S, Plant WD, Morley-Davies A, Sutherland GR. Cardiac involvement in Wegener’s granulomatosis. Br Heart J 1995; 73(2): 110-5.
[http://dx.doi.org/10.1136/hrt.73.2.110 ] [PMID: 7696016]
[74]
Al-Habbaa A, Rawla P, Morra ME, et al. Valvular involvement in granulomatosis with polyangiitis: Case report and systematic review of literature. Echocardiography 2018; 35(9): 1456-63.
[http://dx.doi.org/10.1111/echo.14094 ] [PMID: 29982993]
[75]
Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42(3): 421-30.
[http://dx.doi.org/10.1002/1529-0131(199904)42:3<421:AID-ANR5>3.0.CO;2-6 ] [PMID: 10088763]
[76]
Bai Y-H, Li Z-Y, Chang D-Y, Chen M, Kallenberg CG, Zhao M-H. The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: A study of 504 cases in a single Chinese center. Semin Arthritis Rheum 2018; 47(4): 524-9.
[http://dx.doi.org/10.1016/j.semarthrit.2017.07.004 ] [PMID: 28917713]
[77]
Greco A, Rizzo MI, De Virgilio A, et al. Churg-Strauss syndrome. Autoimmun Rev 2015; 14(4): 341-8.
[http://dx.doi.org/10.1016/j.autrev.2014.12.004 ] [PMID: 25500434]
[78]
Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84(5): 323-30.
[http://dx.doi.org/10.1097/01.md.0000180793.80212.17 ] [PMID: 16148732]
[79]
Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78(1): 26-37.
[http://dx.doi.org/10.1097/00005792-199901000-00003 ] [PMID: 9990352]
[80]
Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72(6): 1011-7.
[http://dx.doi.org/10.1136/annrheumdis-2012-201531 ] [PMID: 22887848]
[81]
Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010; 62(2): 627-34.
[PMID: 20112390]
[82]
Dunogué B, Terrier B, Cohen P, et al. Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. Autoimmun Rev 2015; 14(9): 774-80.
[http://dx.doi.org/10.1016/j.autrev.2015.04.013 ] [PMID: 25960167]
[83]
Marmursztejn J, Guillevin L, Trebossen R, et al. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford) 2013; 52(4): 642-50.
[http://dx.doi.org/10.1093/rheumatology/kes155 ] [PMID: 22772324]
[84]
Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88(4): 236-43.
[http://dx.doi.org/10.1097/MD.0b013e3181af35a5 ] [PMID: 19593229]
[85]
Cheung CC, Constantine M, Ahmadi A, Shiau C, Chen LYC. Eosinophilic myocarditis. Am J Med Sci 2017; 354(5): 486-92.
[http://dx.doi.org/10.1016/j.amjms.2017.04.002 ] [PMID: 29173361]
[86]
Szczeklik W, Tutaj M, Sokołowska B, et al. Impaired cardiovascular autonomic nervous system function in patients with Churg-Strauss syndrome. Scand J Rheumatol 2011; 40(4): 304-7.
[http://dx.doi.org/10.3109/03009742.2010.549500 ] [PMID: 21366384]
[87]
Rieu V, Cohen P, André M-H, et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology (Oxford) 2002; 41(3): 290-300.
[http://dx.doi.org/10.1093/rheumatology/41.3.290 ] [PMID: 11934966]
[88]
Terrier B, Karras A, Cluzel P, et al. Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol 2013; 111(2): 265-72.
[http://dx.doi.org/10.1016/j.amjcard.2012.09.028 ] [PMID: 23116612]
[89]
Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49(1): 69-82.
[http://dx.doi.org/10.1053/j.ajkd.2006.09.015 ] [PMID: 17185147]
[90]
Zaidan M, Mariotte E, Galicier L, et al. Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis. Ann Intensive Care 2012; 2(1): 31.
[http://dx.doi.org/10.1186/2110-5820-2-31 ] [PMID: 22812447]
[91]
Landau D-A, Scerra S, Sene D, Resche-Rigon M, Saadoun D, Cacoub P. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 2010; 37(3): 615-21.
[http://dx.doi.org/10.3899/jrheum.090790 ] [PMID: 20110523]
[92]
Maestroni A, Caviglia AG, Colzani M, et al. Heart involvement in essential mixed cryoglobulinemia. Ric Clin Lab 1986; 16(2): 381-3.
[PMID: 3787099]
[93]
Yavne Y, Tiosano S, Watad A, Comaneshter D, Cohen AD, Amital H. Investigating the link between ischemic heart disease and Behcet’s disease: A cross-sectional analysis. Int J Cardiol 2017; 241: 41-5.
[http://dx.doi.org/10.1016/j.ijcard.2017.02.135 ] [PMID: 28285799]
[94]
Kaseda S, Koiwaya Y, Tajimi T, et al. Huge false aneurysm due to rupture of the right coronary artery in Behcet’s syndrome. Am Heart J 1982; 103(4 Pt 1): 569-71.
[http://dx.doi.org/10.1016/0002-8703(82)90347-7 ] [PMID: 7064796]
[95]
Gao N, Bai R. Clinical characteristics of conduction disturbance in patients with Behcet’s disease. Clin Rheumatol 2018; 37(7): 1921-5.
[http://dx.doi.org/10.1007/s10067-017-3920-2 ] [PMID: 29177984]
[96]
Schiff S, Moffatt R, Mandel WJ, Rubin SA. Acute myocardial infarction and recurrent ventricular arrhythmias in Behcet’s syndrome. Am Heart J 1982; 103(3): 438-40.
[http://dx.doi.org/10.1016/0002-8703(82)90289-7 ] [PMID: 7064781]
[97]
Komatsu T, Chiba N, Yomogida K, et al. A case of Behçet’s disease associated with aortic regurgitation. Kokyu To Junkan 1993; 41(1): 75-80.
[PMID: 8434163]
[98]
Lisitsyna T, Alekberova Z, Ovcharov P, Volkov A, Korsakova J, Nasonov E. Left ventricular intracardiac thrombus in a patient with Behçet disease successfully treated with immunosuppressive agents without anticoagulation: a case report and review of the literature. Rheumatol Int 2015; 35(11): 1931-5.
[http://dx.doi.org/10.1007/s00296-015-3306-1 ] [PMID: 26055535]
[99]
Ayar K, Sensoy B, Aslanci ME, Teker T, Cekic S. Parameters of arterial stiffness in patients with Behçet’s disease and their relationship with disease duration. Rheumatol Int 2019; 39(6): 1053-9.
[http://dx.doi.org/10.1007/s00296-019-04291-y ] [PMID: 30915488]
[100]
Merashli M, Ster IC, Ames PRJ. Subclinical atherosclerosis in Behcet’s disease: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism WB Saunders 2016; 45: 502-10.
[http://dx.doi.org/10.1016/j.semarthrit.2015.06.018]
[101]
Wang H, Guo X, Tian Z, et al. Intracardiac thrombus in patients with Behcet’s disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience. Clin Rheumatol 2016; 35(10): 2501-7.
[http://dx.doi.org/10.1007/s10067-015-3161-1 ] [PMID: 26753545]
[102]
Mavrogeni SI, Kitas GD, Dimitroulas T, et al. Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. Int J Cardiol 2016; 217: 135-48.
[http://dx.doi.org/10.1016/j.ijcard.2016.04.158 ] [PMID: 27179903]
[103]
Mavrogeni SI, Dimitroulas T, Kitas GD. Cardiovascular magnetic resonance in the diagnosis and management of cardiac and vascular involvement in the systemic vasculitides. Curr Opin Rheumatol 2019; 31(1): 16-24.
[PMID: 30407225]
[104]
Mavrogeni S, Papadopoulos G, Hussain T, Chiribiri A, Botnar R, Greil GF. The emerging role of cardiovascular magnetic resonance in the evaluation of Kawasaki disease. Int J Cardiovasc Imaging 2013; 29(8): 1787-98.
[http://dx.doi.org/10.1007/s10554-013-0276-9 ] [PMID: 23949280]
[105]
Sauvetre G, Fares J, Caudron J, et al. Usefulness of magnetic resonance imaging in Churg-Strauss syndrome related cardiac involvement. A case series of three patients and literature review. Rev Med Interne 2010; 31(9): 600-5.
[http://dx.doi.org/10.1016/j.revmed.2010.04.009 ] [PMID: 20605285]
[106]
Rutherford E, Talle MA, Mangion K, et al. Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney Int 2016; 90(4): 845-52.
[http://dx.doi.org/10.1016/j.kint.2016.06.014 ] [PMID: 27503805]
[107]
Misra DP, Shenoy SN. Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int 2017; 37: 151-7.
[http://dx.doi.org/10.1007/s00296-016-3435-1]
[108]
Mavrogeni S. Assessment of cardiovascular involvement in connective tissue disease: let’s open Pandora’s box. Mediterr J Rheumatol 2016; 27: 91-3.
[http://dx.doi.org/10.31138/mjr.27.3.91]
[109]
Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013; 25(1): 3-9.
[http://dx.doi.org/10.1097/BOR.0b013e32835b133a ] [PMID: 23114585]
[110]
Gasparyan AY. Cardiovascular risk and inflammation: pathophysiological mechanisms, drug design, and targets. Curr Pharm Des 2012; 18(11): 1447-9.
[http://dx.doi.org/10.2174/138161212799504777 ] [PMID: 22364139]
[111]
Aksu T, Tufekcioglu O. Intracardiac thrombus in Behçet’s disease: four new cases and a comprehensive literature review. Rheumatol Int 2015; 35(7): 1269-79.
[http://dx.doi.org/10.1007/s00296-014-3174-0 ] [PMID: 25381640]
[112]
Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of Italian society of pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. Ital J Pediatr 2018; 44(1): 103.
[http://dx.doi.org/10.1186/s13052-018-0529-2 ] [PMID: 30157893]
[113]
Cohen TJW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 2013; 27(1): 33-44.
[http://dx.doi.org/10.1016/j.berh.2012.12.004 ] [PMID: 23507055]
[114]
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015; 243(1): 339-43.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.030 ] [PMID: 26448266]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 5
Year: 2020
Published on: 29 January, 2020
Page: [463 - 472]
Pages: 10
DOI: 10.2174/1570161118666200130093432
Price: $65

Article Metrics

PDF: 34
HTML: 1